Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says
Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, an observational study shows. This has been a common concern for metastatic CRPC patients, among whom Xofigo is associated with an increased risk of fractures, particularly when used in combination with other treatments such as  Zytiga (abiraterone acetate) and glucocorticoids. The findings were presented at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 22–25 in Anaheim, California, in a study titled, "Co-treatment with Radium-223 and Enzalutamide: Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) from a Prospective Multicenter Observational Study.” Xofigo, by Bayer, is a kind of internal radiation therapy indicated to treat bone metastasis in prostate cancer patients who no longer respond to hormone therapies — a population with castration-resistant prostate cancer. In combination with other treatments, the therapy significantly extended overall survival and delayed the first bone-related events, compared to a placebo, in metastatic CRPC patients. But when the treatment was
Subscribe or to access all post and page content.